Page 130 - 南京医科大学自然版

第45卷第5期
·716 · 南 京 医 科 大 学 学 报 2025年5月

［14］RUGO H S，BARDIA A，MARMÉ F，et al. Overall survi⁃ cation of 5 ⁃ carboxyfluorescein as a probe substrate of
val with sacituzumab govitecan in hormone receptor⁃posi⁃ SLC46A3 and its application in a fluorescence⁃based in
tive and human epidermal growth factor receptor 2⁃nega⁃ vitro assay evaluating the interaction with SLC46A3［J］.
tive metastatic breast cancer（TROPiCS ⁃ 02）：a ran⁃ Mol Pharm，2023，20（1）：491-499
domised，open⁃label，multicentre，phase 3 trial［J］. Lan⁃ ［25］DIROIO A，HUBERT M，BESSON L，et al. MDR1⁃express⁃
+
cet，2023，402（10411）：1423-1433 ing CD4 T cells with Th1.17 features resist to neoadju⁃
［15］BARDIA A，JHAVERI K，IM S A，et al. LBA11 datopota⁃ vant chemotherapy and are associated with breast cancer
mab deruxtecan（dato⁃DXd）vs chemotherapy in previously clinical response［J］. J Immunother Cancer，2023，11
⁃treated inoperable or metastatic hormone receptor⁃posi⁃ （11）：e007733
tive，HER2⁃negative（HR+/HER2-）breast cancer（BC）： ［26］LI G M，GUO J，SHEN B Q，et al. Mechanisms of acquired
primary results from the randomised phase Ⅲ TROPION⁃ resistance to trastuzumab emtansine in breast cancer
Breast01 trial［J］. Ann Oncol，2023，34：S1264-S1265 cells［J］. Mol Cancer Ther，2018，17（7）：1441-1453
［16］OUYANG Q，YIN Y，SONG L，et al. 380MO SKB264（MK ［27］ENDO Y，LYON S，SHEN Y，et al. Cell proliferation and
⁃ 2870）in previously treated hormone receptor ⁃ positive invasion are regulated differently by EGFR and MRP1 in
（HR+）/HER2⁃negative metastatic breast cancer（mBC）： T⁃DM1⁃resistant breast cancer cells［J］. Sci Rep，2019，9
results from a phase Ⅰ/Ⅱ，single⁃arm，basket trial［J］. （1）：16383
Ann Oncol，2023，34：S337 ［28］CHANG C H，WANG Y，ZALATH M，et al. Combining
［17］LOGANZO F，TAN X Z，SUNG M，et al. Tumor cells ABCG2 inhibitors with IMMU⁃132，an anti⁃trop⁃2 anti⁃
chronically treated with a trastuzumab⁃maytansinoid anti⁃ body conjugate of SN⁃38，overcomes resistance to SN⁃38
body ⁃ drug conjugate develop varied resistance mecha⁃ in breast and gastric cancers［J］. Mol Cancer Ther，2016，
nisms but respond to alternate treatments［J］. Mol Cancer 15（8）：1910-1919
Ther，2015，14（4）：952-963 ［29］JACKMAN M，MARCOZZI C，BARBIERO M，et al. Cy⁃
［18］MOSELE F，DELUCHE E，LUSQUE A，et al. Trastuzum⁃ clin B1⁃Cdk1 facilitates MAD1 release from the nuclear
ab deruxtecan in metastatic breast cancer with variable pore to ensure a robust spindle checkpoint［J］. J Cell Bi⁃
HER2 expression：the phase 2 DAISY trial［J］. Nat Med， ol，2020，219（6）：e201907082
2023，29（8）：2110-2120 ［30］ZHANG J H，FAN J J，ZENG X，et al. Targeting the au⁃
［19］COATES J T，SUN S，LESHCHINER I，et al. Parallel ge⁃ tophagy promoted antitumor effect of T⁃DM1 on HER2⁃
nomic alterations of antigen and payload targets mediate positive gastric cancer［J］. Cell Death Dis，2021，12（4）：288
polyclonal acquired clinical resistance to sacituzumab go⁃ ［31］SABBAGHI M，GIL⁃GÓMEZ G，GUARDIA C，et al. De⁃
vitecan in triple⁃negative breast cancer［J］. Cancer Dis⁃ fective cyclin B1 induction in trastuzumab⁃emtansine（T⁃
cov，2021，11（10）：2436-2445 DM1）acquired resistance in HER2⁃positive breast can⁃
［20］BEENKEN A，CERUTTI G，BRASCH J，et al. Structures cer［J］. Clin Cancer Res，2017，23（22）：7006-7019
of LRP2 reveal a molecular machine for endocytosis［J］. ［32］MARTIN M，FUMOLEAU P，DEWAR J A，et al. Trastu⁃
Cell，2023，186（4）：821-836 zumab emtansine（T⁃DM1）plus docetaxel with or without
［21］KARCINI A，MERCIER N R，LAZAR I M. Proteomic pertuzumab in patients with HER2 ⁃ positive locally ad⁃
assessment of SKBR3/HER2+breast cancer cellular res⁃ vanced or metastatic breast cancer：results from a phase
ponse to lapatinib and investigational ipatasertib kinase ib/IIa study［J］. Ann Oncol，2016，27（7）：1249-1256
inhibitors［J］. Front Pharmacol，2024，15：1413818 ［33］KROP I E，MODI S，LORUSSO P M，et al. Phase 1b/2a
［22］WANG H B，WANG W Q，XU Y P，et al. Aberrant intra⁃ study of trastuzumab emtansine（T⁃DM1），paclitaxel，and
cellular metabolism of T⁃DM1 confers T⁃DM1 resistance pertuzumab in HER2⁃positive metastatic breast cancer［J］.
in human epidermal growth factor receptor 2⁃positive gas⁃ Breast Cancer Res，2016，18（1）：34
tric cancer cells［J］. Cancer Sci，2017，108（7）：1458- ［34］CORTÉS J，DIÉRAS V，LORENZEN S，et al. Efficacy and
1468 safety of trastuzumab emtansine plus capecitabine vs
［23］TOMABECHI R，KISHIMOTO H，SATO T，et al. trastuzumab emtansine alone in patients with previously
SLC46A3 is a lysosomal proton⁃coupled steroid conjugate treated ERBB2（HER2）⁃ positive metastatic breast can⁃
and bile acid transporter involved in transport of active ca⁃ cer：a phase 1 and randomized phase 2 trial［J］. JAMA
tabolites of T ⁃ DM1［J］. PNAS Nexus，2022，1（3）： Oncol，2020，6（8）：1203-1209
pgac063 ［35］ZHANG J，LI J Y，ZHU C J，et al. Safety and efficacy of
［24］TOMABECHI R，MIYASATO M，SATO T，et al. Identifi⁃ the addition of pertuzumab to T⁃DM1 ± taxane in patients